Erste Group Bank Reiterates Hold Rating for Amgen (NASDAQ:AMGN)

Key Points

• Erste Group Bank reissued a Hold rating on Amgen (AMGN) in its latest research note.
• Analyst consensus remains a Hold with an average price target of $357.12 (rating distribution: 1 Strong Buy, 13 Buy, 15 Hold, 2 Sell), indicating mixed expectations for upside.
• Amgen beat Q1 EPS expectations ($5.15 vs. $4.77) and set FY2026 guidance of 21.700–23.100 EPS (analysts average 22.28), while announcing a $300 million U.S. manufacturing expansion to boost capacity and supply resilience.

Amgen (NASDAQ:AMGN - Get Free Report)'s stock had its "hold" rating reissued by equities research analysts at Erste Group Bank in a research note issued to investors on Tuesday, MarketBeat.com reports.

A number of other equities analysts have also recently weighed in on the company. Deutsche Bank Aktiengesellschaft boosted their price target on Amgen from $285.00 to $295.00 and gave the stock a "hold" rating in a report on Thursday, February 5th. Citigroup boosted their price target on Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. TD Cowen restated a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Freedom Capital lowered Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 12th. Finally, Leerink Partners restated a "market perform" rating and issued a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $357.12.

Amgen Trading Down 1.8%

AMGN opened at $323.85 on Tuesday. The company has a quick ratio of 0.90, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market cap of $174.78 billion, a price-to-earnings ratio of 22.54, a price-to-earnings-growth ratio of 3.24 and a beta of 0.44. Amgen has a 52 week low of $261.43 and a 52 week high of $391.29. The business's 50 day moving average is $358.07 and its two-hundred day moving average is $341.12.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 earnings per share. The business's quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts predict that Amgen will post 22.28 EPS for the current year.

Institutional Investors Weigh In On Amgen

A number of hedge funds have recently bought and sold shares of the business. Cornerstone Advisory LLC boosted its stake in shares of Amgen by 3.1% during the 1st quarter. Cornerstone Advisory LLC now owns 2,013 shares of the medical research company's stock valued at $708,000 after buying an additional 61 shares during the last quarter. Adell Harriman & Carpenter Inc. increased its stake in shares of Amgen by 2.6% in the first quarter. Adell Harriman & Carpenter Inc. now owns 22,575 shares of the medical research company's stock worth $7,943,000 after buying an additional 567 shares during the last quarter. Checchi Capital Advisers LLC raised its holdings in Amgen by 8.8% in the first quarter. Checchi Capital Advisers LLC now owns 6,558 shares of the medical research company's stock valued at $2,307,000 after acquiring an additional 531 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in Amgen by 0.9% in the first quarter. Maryland State Retirement & Pension System now owns 27,051 shares of the medical research company's stock valued at $9,518,000 after acquiring an additional 242 shares in the last quarter. Finally, Calamos Advisors LLC boosted its stake in Amgen by 5.1% during the 1st quarter. Calamos Advisors LLC now owns 75,496 shares of the medical research company's stock valued at $26,563,000 after acquiring an additional 3,648 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced an additional $300 million investment to expand U.S. manufacturing (Puerto Rico/Juncos), aiming to boost capacity, next‑generation technology and supply resilience — a long‑term positive for production reliability and commercial supply. Amgen to invest additional $300 million to boost US manufacturing footprint
• Neutral Sentiment: Investor attention pieces and screen interest (coverage by Zacks and other outlets) note Amgen is in focus, but they don’t introduce new fundamental catalysts — this may increase trading volume without changing the company’s near‑term fundamentals. Amgen Inc. (AMGN) is Attracting Investor Attention
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 from $351 and kept a Neutral rating — a downgrade in analyst expectations that reduces implied upside and can pressure sentiment. Amgen NASDAQ: AMGN Given New $340.00 Price Target at Guggenheim
• Negative Sentiment: Broader health‑care sector weakness in afternoon trading is weighing on AMGN along with peers, amplifying downward pressure independent of company‑specific news. Sector Update: Health Care Stocks Softer in Afternoon Trading

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.